Structurally novel kappa opioid receptor antagonists areprovided and the use of these antagonists in treatment of diseasestates that are ameliorated by binding of the kappa opioid receptorsuch as heroin or cocaine addictions.
Kappa opioid receptor ligands
Carroll, F., Thomas, J., & Mascarella, S. (2003). IPC No. U.S. Kappa opioid receptor ligands. (U.S. Patent No. 6559159).